XBI’s small-caps replicate the performance of the mid-caps
The SPDR S&P Biotech ETF’s (XBI) small-cap stocks replicated the performance of the mid-cap stocks. They returned 2.3%. The small-cap stocks also outperformed XBI and the SPDR S&P Biotech ETF (SPY) on November 25, 2015. Among the 59 small-cap stocks in XBI’s holdings, 49 stocks gave positive returns and ten stocks ended up in red. The small-cap stocks account for ~55.5% of XBI’s portfolio. XBI’s small-cap stocks include stocks like Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Celldex Therapeutics (CLDX). They had returns of 4.8%, 0.1%, and 0.55%, respectively.
The above graph shows the performance of XBI’s small-cap stocks compared to XBI and SPY. Since the beginning of November 2015 to date, XBI’s small-cap stocks outperformed XBI and SPY. XBI’s small-cap stocks gave a return of 10.2%. XBI returned 8.8% and SPY returned 0.7%.
Immunogen rose by 7.2%
Immunogen (IMGN) rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It’s important to note that there were ~1.3 million shares traded compared to the five-day average trading volume of ~916,000 shares per day. Immunogen closed at $13.76. It passed the 100-day moving average price of $13.48. It was also trading above the 50-day and 20-day moving averages. With the RSI (Relative Strength Index) at 57, the stock isn’t overbought or oversold. The median analyst target price for the stock is $16. Six analysts recommended a “buy” and one analyst recommended a “sell” on the stock. Immunogen has a book value of $0.13 per share. With its current price, the stock is trading at a PBV (price-to-book value) ratio of 103.1x compared to the funds industry average of 13.16x. Immunogen has a weight of ~1% in XBI’s portfolio.